Avenue Therapeutics
ATXI69
$2.04arrow_drop_up1.49%$0.03
High Value
High Growth
Penny Stock
ATXI69
$2.04
arrow_drop_up1.49%Performance History
| Key Stats | |
|---|---|
| Open | $1.95 |
| Prev. Close | $2.01 |
| EPS | 24.78 |
| Dividend | Non-Dividend |
| Next Earnings Date | - |
| Dividend Yield % | - |
| Market Cap | $2.79M |
| LOW | HIGH | |
|---|---|---|
| Day Range | 1.95 | 2.04 |
| 52 Week Range | 1.63 | 50.62 |
| Ratios | |
|---|---|
| Revenue | - |
| EBITDA Margin % | - |
| EPS | 24.78 |
Score Breakdown
Welcome to Stocklytics
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Analyst Forecast
Period: Next 12 Months
•Analyst Ratings
••
About Avenue Therapeutics (ATXI)
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Alexandra MacLean M.D.
- Headquarters
- Tampa
- Employees
- 2
- Exchange
- NASDAQ
Keep an eye on Avenue Therapeutics
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Frequently Asked Questions
help
What is Avenue Therapeutics 's (ATXI) price per share?
The current price per share for Avenue Therapeutics (ATXI) is $2.04. The stock has seen a price change of $0.03 recently, indicating a 1.49% change. This reflects the stock's recent market performance and investor sentiment.
help
What is the 52-week high and low for Avenue Therapeutics (ATXI)?
For Avenue Therapeutics (ATXI), the 52-week high is $50.62, which is 2.38K% from the current price. The 52-week low is $1.64, the current price is 24.77% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help
Is Avenue Therapeutics (ATXI) a growth stock?
Avenue Therapeutics (ATXI) has shown an average price growth of -7.23% over the past three years. It has received a score of 96 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Avenue Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help
What is Avenue Therapeutics (ATXI) stock price performance year to date (YTD)?
As of the latest data, Avenue Therapeutics (ATXI) has a year-to-date price change of -83%. Over the past month, the stock has experienced a price change of 2%. Over the last three months, the change has been -28.42%. Over the past six months, the figure is -46.46%. Looking at a longer horizon, the five-year price change stands at -99.97%.
help
Is Avenue Therapeutics (ATXI) a profitable company?
Avenue Therapeutics (ATXI) has a net income of -$10.38M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$14.54M. Furthermore, the EBITDA is $0.
help
What is the market capitalization of Avenue Therapeutics (ATXI)?
Avenue Therapeutics (ATXI) has a market capitalization of $2.83M. The average daily trading volume is 2, indicating the stock's liquidity and investor engagement.
News
CALENDAR OF EVENTS
CONFERENCE CALLS/ WEBCASTS
Avenue Therapeutics to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
CLINICAL STUDY
Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)
EARNINGS RELEASES AND OPERATING RESULTS
Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
WARRANTS AND CERTIFICATES
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
MAJOR SHAREHOLDER ANNOUNCEMENTS
Avenue Therapeutics Announces Reverse Stock Split
CALENDAR OF EVENTS
Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024